A positive cash flow allows us to invest in-kind support and share the risk and thus the incentive for drug development with our partners.

With our unique financial risk-sharing models, we are truly aligned with our partners and share the same, ultimate goal: To quickly reach the market with high-quality data while avoiding delays in recruitment and monitoring.

Our achievements in previous and on-going partnerships demonstrate superior capabilities in these models within osteoarthritis and osteoporosis.

Please contact us for more information about our financial risk-sharing model and opportunities.